Skip to main content

Table 5 Estimated effect (EE) and effect size (ES) of early engagement in External Facilitation

From: Expanding access to medications for opioid use disorder in primary care clinics: an evaluation of common implementation strategies and outcomes

  Early engagement with a prescriber vs. Did not engage Early engagement without a prescriber vs. Did not engage Early engagement with a prescriber vs. Early engagement without a prescriber
Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3
Reach
Number of patients with OUD
  EE (95% CI) 17.32 (2726.97, 2761.61) 6.72 (1381.52, 1394.96) 3.88 (2748.17, 2740.41) 13.02 (3292.76, 3318.81) 16.54 (1687.17, 1720.25) 20.05 (3286.25, 3326.35) 4.30 (1234.21, 1242.81) 9.82 (640.28, 620.64) 23.93 (1263.53, 1215.66)
  ES (95% CI) 0.21 (33.05, 33.47) 0.08 (16.75, 16.91) 0.05 (33.31, 33.22) 0.16 (39.91, 40.23) 0.20 (20.45, 20.85) 0.24 (39.83, 40.32) 0.05 (14.96, 15.06) 0.12 (7.76, 7.52) 0.29 (15.32, 14.74)
Number of patients prescribed MOUD
  EE (95% CI) 15.68 (61.70, 93.06) 2.51 (52.70, 57.72) 10.66 (88.04, 66.72) 14.99 (80.07, 110.05) 5.38 (63.47, 74.23) 4.24 (99.29, 90.82) 0.69 (35.35, 36.74) 2.87 (28.97, 23.23) 6.43 (42.47, 29.62)
  ES (95% CI) 0.98 (3.84, 5.79) 0.16 (3.28, 3.59) 0.66 (5.48, 4.15) 0.93 (4.98, 6.85) 0.34 (3.95, 4.62) 0.26 (6.18, 5.65) 0.04 (2.20, 2.9) 0.18 (1.80, 1.45) 0.40 (2.64, 1.84)
Percent of patients prescribed MOUDa
  EE (95% CI) 4.90 (3.00, 12.79) 2.34 (8.90, 4.22) −9.58 (−17.11, −2.05) 6.91 (0.59, 14.41) 5.67 (11.48, 0.14) −18.25 (−25.22, −11.29) 2.01 (6.06, 2.03) 3.33 (0.85, 5.81) 8.68 (4.07, 13.28)
  ES (95% CI) 0.13 (0.08, 0.35) 0.06 (0.24, 0.11) −0.26 (−0.46, −0.06) 0.19 (0.02, 0.39) 0.15 (0.31, 0.00) −0.49 (−0.68, −0.31) 0.05 (0.16, 0.06) 0.09 (0.02, 0.16) 0.23 (0.11, 0.40)
Adoption
Number of prescribers
  EE (95% CI) 2.42 (6.71, 11.54) 2.42 (5.84, 10.69) 2.43 (6.69, 11.56) 2.61 (8.39, 13.61) 2.60 (7.38, 12.58) 2.59 (8.41, 13.59) 0.19 (3.72, 3.34) 0.17 (3.32, 2.97) 0.15 (3.68, 3.38)
  ES (95% CI) 0.52 (1.45, 2.50) 0.53 (1.264, 2.314) 0.53 (1.45, 2.50) 0.57 (1.82, 2.95) 0.56 (1.60, 2.72) 0.56 (1.821, 2.940) 0.04 (0.81, 0.72) 0.04 (0.72, 0.64) 0.03 (0.80, 0.93)
Number of x-waivered prescribers
  EE (95% CI) 0.53 (2.68, 3.73) 0.14 (2.70, 2.98) 0.24 (3.45, 2.96) 0.92 (3.05, 4.90) 0.20 (3.35, 3.74) 0.53 (4.50, 3.44) 0.40 (1.90, 1.11) 0.06 (1.40, 1.11) 0.28 (1.22, 1.79)
  ES (95% CI) 0.17 (0.89, 1.24) 0.05 (0.89, 0.99) 0.08 (1.14, 0.98) 0.31 (1.01, 1.62) 0.07 (1.11, 1.24) 0.18 (1.49, 1.14) 0.13 (0.63, 0.37) 0.02 (0.46, 0.43) 0.10 (0.40, 0.59)
Number of active x-waivered prescribers
  EE (95% CI) 0.62 (0.48, 1.73) 0.14 (0.77, 1.05) 0.34 (1.44, 0.76) 0.94 (0.43, 2.32) 0.47 (0.68, 1.61) 0.01 (1.38, 1.36) 0.32 (0.84, 0.19) 0.33 (0.76, 0.10) 0.33 (0.85, 0.19)
  ES (95% CI) 0.34 (0.26, 0.94) 0.08 (0.42, 0.57) 0.19 (0.79, 0.42) 0.51 (0.23, 1.26) 0.25 (0.37, 0.88) 0.01 (0.75, 0.74) 0.18 (0.46, 0.11) 0.18 (0.41, 0.06) 0.18 (0.46, 0.10)
Percent of x-waivered prescribers
  EE (95% CI) 1.79 (0.20, 3.78) 0.52 (1.31, 2.35) 0.75 (2.75, 1.24) 6.08 (3.61, 8.56) 3.08 (0.80, 5.37) 0.08 (2.39, 2.56) −4.30 (−5.17, −3.42) −2.57 (−3.36, −1.77) 0.84 (1.71, 0.04)
  ES (95% CI) 0.08 (0.01, 0.17) 0.02 (0.06, 0.11) 0.03 (0.13, 0.06) 0.28 (0.16, 0.39) 0.14 (0.04, 0.24) 0.00 (0.11, 0.12) −0.20 (−0.24, −0.16) −0.12 (−0.15, −0.08) 0.04 (0.08, 0.00)
Implementation
IMAT implementation quality
  EE (95% CI) −0.36 (−0.53, −0.20) 0.11 (0.31, 0.10) −0.25 (−0.33, −0.18)
  ES (95% CI) −0.60 (−0.87, −0.33) 0.18 (0.52, 0.16) −0.42 (−0.55, −0.29)
  1. aPrimary outcome; EE and ES in bold indicated 95% CI did not cross